首页> 美国卫生研究院文献>other >A Preliminary Trial: Double-Blind Comparison of Nefazodone Bupropion-SR and Placebo in the Treatment of Cannabis Dependence
【2h】

A Preliminary Trial: Double-Blind Comparison of Nefazodone Bupropion-SR and Placebo in the Treatment of Cannabis Dependence

机译:初步试验:奈法唑酮安非他酮-SR和安慰剂对大麻依赖的双盲比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study investigated the efficacy of nefazodone and bupropion-sustained release for treating cannabis dependence. A double blind, placebo controlled, piggy back design was employed to assess if nefazodone and bupropion-sustained release increased the probability of abstinence from cannabis and reduced the severity of cannabis dependence and cannabis withdrawal symptoms during a 13-week outpatient treatment program. One-hundred and six participants (M=32 years; Females n=25) were randomized to one of three medication conditions (nefazodone, bupropion-sustained release, or placebo) and participated in a weekly individually based coping skills therapy program. Results indicated a an increased probability of achieving abstinence over the course of treatment and a decrease in the severity of cannabis dependence and the withdrawal symptom of irritability. There were no significant effects demonstrated for nefazodone and bupropion-sustained release on cannabis use or cannabis withdrawal symptoms. The results indicate nefazodone and bupropion-sustained release may have limited efficacy in treating cannabis dependence.
机译:本研究调查了奈法唑酮和安非他酮缓释剂治疗大麻依赖的功效。在13周的门诊治疗方案中,采用了双盲,安慰剂对照的背piggy式设计来评估奈法唑酮和安非他酮缓释是否增加了戒酒的可能性,并降低了大麻依赖和大麻戒断症状的严重性。一百零六名参与者(M = 32岁;女性n = 25)被随机分配到三种药物治疗条件(奈法唑酮,安非他酮缓释剂或安慰剂)中的一种,并参加了每周一次的个人应对技能治疗计划。结果表明,在治疗过程中获得戒酒的可能性增加,大麻依赖的严重性和烦躁的戒断症状降低。没有证明奈法唑酮和安非他酮持续释放对大麻使用或大麻戒断症状有明显影响。结果表明,奈法唑酮和安非他酮缓释剂在治疗大麻依赖方面的疗效可能有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号